Salutaris Medical Devices Team
Ryan Lohrenz has served as the CEO of the company since March of 2017. Previously, he was responsible for the design and development of the current SMD-DA Applicator and Source. He brings 10+ years of management, engineering, and medical product design and development experience to SalutarisMD. Ryan has significant previous experience the 510(k) process and CE Marking of new devices at Bioptics (presently Faxitron X-Ray). He received a Bachelor of Science degree in Mechanical Engineering from the University of Arizona.
Mary Drew has been with Salutaris Medical Devices, Inc. since 2010 and has more than 15 years of experience working in clinical trials. She has participated in studies in various therapeutic areas including; cardiology, endocrinology, pain, dermatology and women’s health. She holds a Master’s Degree in Clinical Research Management from Arizona State University and a Bachelor’s Degree in Microbiology from Minnesota State University Mankato.
Hailey Davenport has held the position of Clinical Data Coordinator at Salutaris Medical Devices since May, 2017. After receiving a Bachelor’s Degree in Biomedical Engineering from the University of Arizona, she continued her undergraduate translational research, coauthoring multiple scientific publications in the field of molecular endocrinology. She has held positions as a Research Specialist and Clinical Research Coordinator for the University of Arizona, working on many clinical trials in the therapeutic areas of Surgery, Emergency Medicine, and Precision Medicine.
With nearly 20 years of healthcare product experience, Michelle Lott has distinguished herself in the industry with uniquely simple solutions to complex regulatory challenges. Michelle’s specialties include crafting successful regulatory submissions and quality management systems for startup companies. She founded Lean RAQA, LLC, a Regulatory and Quality system solutions company, with the mission to Make Quality Make Sense™. She has previously held executive leadership roles for international regulatory and quality operations. Michelle is currently serving on the FDA’s Device Good Manufacturing Practices (DGMP) Advisory Committee as an industry representative, providing strategy and guidance to FDA on key topics.
Medical Advisory Team
Russell Hamilton, PhD
Dr. Hamilton is a medical physicist specializing in radiation therapy (RT) certified by two boards (American Board of Radiology, American Board of Medical Physics). He is currently a tenured professor at the University of Arizona (UA). After graduating summa cum laude with a BS in Physics from the University of Illinois, he earned a PhD at Stanford University studying theoretical astrophysics. He entered medical physics on a fellowship at the University of Chicago where he eventually became a faculty member. He left Chicago to become Physics Section Head in Radiation Oncology the UA. His clinical focus is on improving patient care by incorporating innovative technology. His research applies mathematical methods to problems in RT. He has published over 50 peer reviewed articles and holds nine patents. Dr. Hamilton founded the medical physics graduate and residency program at UA. He provides classroom instruction and practical clinical training for all levels of RT professionals. Dr. Hamilton has served as the Director or Chair of several UA Committees associated with the use of Radiation.
Luca Brigatti, MD
Dr. Brigatti is a licensed ophthalmologist with a specialization in glaucoma and extensive clinical and research experience. He has contributed to the execution of numerous clinical trials for ophthalmic therapeutics and clinical practices. He also hold several U.S. patents as a co-inventor of Salutaris Medical Devices’ novel minimally invasive brachytherapy device. His unique perspective as a Glaucoma specialist led to the development of the technique used by SalutarisMD to deliver radiation to the posterior of the eye in a minimally invasive fashion. As one of the founders of Salutaris Medical Devices, Dr. Brigatti’s intimate knowledge of this technology and its development is critical in the advancement of this device in routine clinical use.
Baldassarre Stea, MD, PhD
Dr. Stea is board-certified in radiation oncology, and specializes in the treatment of malignant and benign brain tumors using stereotactic radiosurgery (SRS). He developed the stereotactic radiosurgery program at the University of Arizona, and have more than 20 years of experience in the field. His research is focused on the development of novel radiation enhancers and radio-sensitizing drugs for primary and secondary brain tumors, and his clinical practice focuses on treatment of malignant brain tumors and pediatric cancers, including total body irradiation (TBI). Dr. Stea has received the UMC ``Patient's Choice Award`` for outstanding communication and excellence in patient care 1994, 1995 and 1998, and has been listed among The Best Doctors in America continuously since 1996.
Rama Jager, MD, MBA, FACS
Dr. Jager completed his ophthalmology residency at the University of Chicago and completed his vitreoretinal fellowship at the Joslin Diabetes Center at Harvard Medical School. He specializes in the medical and surgical diseases of the retina, vitreous, and macula. Dr. Jager utilizes state-of-the-art technology in the management of age-related macular degeneration, retinal vascular occlusions, diabetic retinopathy, retinal detachment surgery, macular hole surgery, diabetic surgery, and epiretinal membrane surgery. He has co-authored over 100 articles, book chapters, abstracts, and presentations, and serves as Clinical Professor of Ophthalmology at the University of Illinois at Chicago. He is dedicated to the surgical teaching and mentoring vitreoretinal fellows, residents, and medical students and new physicians, and has received awards for excellence in teaching. Dr. Jager has participated in over 30 clinical trials in ophthalmology and has co-authored 3 books in ophthalmology.
Gregg Kokame, MD, MMM
Dr. Kokame completed his ophthalmology residency at the Jules Stein Eye Institute at the UCLA School of Medicine and completed his Vitreoretinal Surgery Fellowship at Bascom Palmer Eye Institute at the University of Miami School of Medicine in Miami, Florida. Dr. Kokame is a Clinical Professor at the University of Hawaii John A. Burns School of Medicine, where he teaches international vitreoretinal fellows, residents, interns and medical students about retinal diseases. He has directed The Retina Center at Pali Momi into a nationally and internationally recognized center for retinal research and education. Many new clinical trials bringing new advances over the last decade have initially started in Hawaii as clinical trials at The Retina Center at Pali Momi. He has authored over 70 scientific papers in peer-reviewed journals, and is a consultant and reviewer for all the major journals in ophthalmology.
Board of Directors
George Mimura is an active equity investor in biotechnology, software, and real estate. He enjoyed a 25-year career in international finance, where he held senior management positions in New York, Tokyo, London, and Sydney. He helped to create and manage profitable business units at Mitsubishi UFJ Morgan Stanley, Nomura, Bankers Trust, and Citibank. He has expertise managing equity proprietary trading strategies and trading fix-income and currency derivatives. Currently, he serves as a Director at Cerego, LLC. He served as a FINRA District 10 Committee Member. He is a graduate of Georgetown University.
Robert Selby, MD is a private equity investor in biotechnology and commercial real estate. He has spent most of his career in the private practice of clinical Dermatology. He has served as clinical instructor at the University of Arizona School of Medicine, Department of Internal Medicine and Dermatology with the position of Assistant Professor of Internal Medicine. He is a graduate of the University of Arizona and completed board certification in both Internal Medicine and Dermatology.
William is the Founder and Chairman of Coulter Ridge Capital, a firm investing in early stage companies, primarily healthcare related. His expertise is in the area of rapidly growing service companies, beginning with Humana, where he was Senior Vice President-Finance and Treasurer. He has served as the Secretary of Commerce of the Commonwealth of Kentucky and has founded several entrepreneurial companies in the health care services area. He also serves on the boards of numerous young, entrepreneurial companies and is a General Partner of an early stage Venture Capital Fund located in Louisville, KY. He earned his B.A. from the College of Wooster and his M.B.A. from Wharton Graduate School of the University of Pennsylvania.
William Mumma is CEO and Chairman of the Board for the Becket Fund for Religious Liberty, a non-profit, public interest law firm headquartered in DC. He ended a 30 year career on Wall Street in 2012 as CEO of Mitsubishi UFJ Securities (USA), with prior senior executive roles at Nomura Securities International and the Bankers Trust Company in New York. Mr. Mumma is also currently serving as Trustee on the boards of the Witherspoon Institute in Princeton, the Religious Freedom Institute at Georgetown and FOCUS (The Fellowship of Catholic University Students) in Colorado. He graduated from Georgetown University’s School of Foreign Service in 1981and earned his MBA at Columbia University Business School in 1983.
Eric Tooker, JD
Eric currently serves as Vice President and General Counsel of Translational Drug Development, LLC, a specialty oncology CRO. He is also a Manager of Translational Accelerator, LLC, a $20 million biotech venture fund based in Phoenix, Arizona. Previously, Mr. Tooker served as President and Chief Executive Officer of MCS Biotech Resources, which provides business, legal, administrative, and support services to startup companies. Mr. Tooker has extensive experience in advising executive business teams throughout his 28 years as in-house counsel. In that role with Conseco, Inc., he served as legal counsel and business adviser for a significant private equity portfolio. Mr. Tooker earned a B.S. degree in education from Miami University-Ohio and a J.D. from the University of Michigan Law School.